InterMune (ITMN) +89% premarket after EU's CHMP recommends its lung disease treatment Esbriet...

|By:, SA News Editor

InterMune (ITMN) +89% premarket after EU's CHMP recommends its lung disease treatment Esbriet even earlier than expected. FDA rejected the drug in May, sending shares off a cliff. Esbriet would be the first effective treatment for the fatal disease idiopathic pulmonary fibrosis.